Phaseline

Targets › CBL-B

CBL-B: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: the race on CBL-B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nurix TherapeuticsNX-1607
Cbl-b inhibitor
CBL-BPhase 1Ovarian Cancer, EpithelialFeb 2028

Conditions

Ovarian Cancer, Epithelial (1)

Modalities

small molecule (1)

Companies

Nurix Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.